Back to Directory
Pegbelfermin
Anti-Aging & LongevityPEGylated FGF-21 analog for NASH and metabolic diseases.
Key Benefits
- ✓Reduces liver fat
- ✓Improves metabolic parameters
- ✓Treats NASH
- ✓Weight loss
- ✓Improves lipid profiles
Dosing Information
Dosage Range
Under investigation
Frequency
Weekly in trials
Typical Duration
Clinical trials
Detailed Protocol
Under clinical investigation. Administered via subcutaneous injection weekly in trials. Not yet approved.
About Pegbelfermin
Pegbelfermin (BMS-986036) is a PEGylated FGF-21 analog being developed for non-alcoholic steatohepatitis (NASH). Phase 2 trials showed improvements in liver fat and fibrosis biomarkers.
Research Notes
Phase 2 trials showed promising NASH results but development status unclear. Part of FGF-21 class of metabolic therapeutics.
Potential Side Effects
- •Diarrhea in some patients
- •Generally well tolerated
- •Investigational
Always consult with a healthcare professional before starting any peptide therapy.